Study of Plasmodium vivax Mutations and Drug Response in Madagascar
Author Information
Author(s): Céline Barnadas, Magali Tichit, Christiane Bouchier, Arsène Ratsimbasoa, Laurence Randrianasolo, Rogelin Raherinjafy, Martial Jahevitra, Stéphane Picot, Didier Ménard
Primary Institution: Institut Pasteur de Madagascar
Hypothesis
What is the prevalence of P. vivax mutations and their correlation with treatment response to sulphadoxine-pyrimethamine in Madagascar?
Conclusion
The study found that a significant proportion of P. vivax infections in Madagascar have mutations associated with resistance to sulphadoxine-pyrimethamine, indicating potential treatment failures.
Supporting Evidence
- 71% of P. vivax samples had mutations in the pvdhfr gene.
- 19% of patients were classified as treatment failures after 28 days.
- The study identified two novel mutations in the pvdhfr gene.
- The prevalence of P. vivax infections was estimated at 6.3% among malaria cases.
Takeaway
This study looked at how a type of malaria called P. vivax is changing and how well a common medicine works against it in Madagascar. They found that many of the malaria germs have changed in ways that might make the medicine less effective.
Methodology
Clinical isolates of P. vivax were collected from patients in Madagascar, and the pvdhfr and pvdhps genes were sequenced to analyze mutations and treatment responses.
Potential Biases
There may be biases related to the selection of patients and the reliance on specific diagnostic methods.
Limitations
The study's findings may be limited by the small sample size and the potential for underreporting of P. vivax infections.
Participant Demographics
Participants included 16 patients aged from 9 months to 42 years, with a median age of 7.5 years.
Statistical Information
P-Value
0.05
Confidence Interval
95% CI: 5%–43%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website